Ratnakar Securities Pvt. Ltd.

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin

BSE1993.70-5.5 (-0.28 %)

PREV CLOSE ( ) 1999.20

OPEN PRICE ( ) 2015.25

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 70242

TODAY'S LOW / HIGH ( )1982.60 2015.25

52 WK LOW / HIGH ( )1531.15 2403.45

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1983

Management Info

Manju D Gupta - Chairman Nilesh Gupta - Managing Director

Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

09Jun Lupin gets USFDAâ€™s approval for Oxca
Lupin has received tentative approval from the United States Food and Dr..

26May Lupin enters into license, supply agre
Lupin has entered into a license and supply agreement with SteinCares, a..

26May Lupin gains on entering into license,
Lupin is currently trading at Rs 1990.70, up by 11.65 points or 0.59% fr..

26May Lupin informs about press release
Lupin has informed that it enclosed a Press Release as regards, the Comp..

20May Lupin, Honeywell move forward jointly
Lupin is planning to use Honeywellâ€™s Solstice Air (HFO-1234ze cGMP) pr..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	12913.5	39729.6
Gross Profit	15530.9	48371.2
Operating Profit	17949.2	56465.3
Net Sales	44856.7	169675

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 10035.75 (2.49%)	M.Cap ( in Cr)25089.38
Procter&Gamble Healt (BSE) 5689.95 (2.51%)	M.Cap ( in Cr)9444.97
Concord Biotech (BSE) 2013.45 (4.47%)	M.Cap ( in Cr)21063.95
Divi's Lab (BSE) 6626.15 (1.14%)	M.Cap ( in Cr)175903.46
Sanofi Cons. Health (BSE) 5124.20 (1.44%)	M.Cap ( in Cr)11801.35

Shareholding Pattern

	FI/BANKS/INSURANCE	6.34%
	NON-INSTITUTION	6.2%
	PROMOTERS	46.92%
	MUTUAL FUNDS/UTI	17.55%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Tata Nifty MidSmall...	8.90
Motilal Oswal Nifty...	8.88
Nippon India Pharma...	7.27
Nippon India Nifty ...	6.52
ICICI Pru Nifty Pha...	6.48
Mirae Asset Healthc...	6.20

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

LUPIN LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES